Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2013 1
2014 1
2015 2
2016 5
2017 5
2018 7
2019 7
2020 14
2021 15
2022 12
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of HER2-low expression from primary to recurrent breast cancer.
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: lo mele m. NPJ Breast Cancer. 2021 Oct 12;7(1):137. doi: 10.1038/s41523-021-00343-4. NPJ Breast Cancer. 2021. PMID: 34642348 Free PMC article.
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Vernaci G, Savarino EV, Patuzzi I, Facchin S, Zingone F, Massa D, Faggioni G, Giarratano T, Miglietta F, Griguolo G, Fassan M, Lo Mele M, Gasparini E, Bisagni G, Guarneri V, Dieci MV. Vernaci G, et al. Among authors: lo mele m. Oncologist. 2023 Sep 7;28(9):e703-e711. doi: 10.1093/oncolo/oyad060. Oncologist. 2023. PMID: 36940301 Free PMC article.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: lo mele m. Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480. Clin Cancer Res. 2023. PMID: 37417941 Free PMC article.
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.
Miglietta F, Carraro V, Amato O, Griguolo G, Bottosso M, Munari G, Zarrilli G, Lo Mele M, Barbieri C, Dei Tos AP, Guarneri V, Dieci MV, Fassan M. Miglietta F, et al. Among authors: lo mele m. J Clin Pathol. 2023 Jun 21:jcp-2023-208856. doi: 10.1136/jcp-2023-208856. Online ahead of print. J Clin Pathol. 2023. PMID: 37344170 Free article.
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy.
Girardi F, Marini S, Porra F, Carpentieri S, Marchet A, Saibene T, Lo Mele M, Giarratano T, Giorgi CA, Mioranza E, Falci C, Faggioni G, Caumo F, Griguolo G, Dieci MV, Guarneri V. Girardi F, et al. Among authors: lo mele m. Oncologist. 2023 Dec 11;28(12):e1179-e1184. doi: 10.1093/oncolo/oyad255. Oncologist. 2023. PMID: 37699107 Free PMC article. Review.
Effect of a Phytogenic Feed Additive in Preventing Calves' Diarrhea.
Turini L, Mantino A, Tozzi B, Bonelli F, Silvi A, Mele M, Sgorbini M, Meucci V, Minieri S. Turini L, et al. Among authors: mele m. Front Vet Sci. 2022 May 11;9:873194. doi: 10.3389/fvets.2022.873194. eCollection 2022. Front Vet Sci. 2022. PMID: 35647110 Free PMC article.
75 results